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Abstract
Background: Endothelin-1 (ET-1) is a potent vasoactive peptide, which induces vasoconstriction
and proliferation in vascular smooth muscle cells (VSMCs) through activation of endothelin type A
(ETA) and type B (ETB) receptors. The extracellular signal-regulated kinase 1 and 2 (ERK1/2)
mitogen-activated protein kinases (MAPK) are involved in ET-1-induced VSMC contraction and
proliferation. This study was designed to investigate the ETA and ETB receptor intracellular signaling
in human VSMCs and used phosphorylation (activation) of ERK1/2 as a functional signal molecule
for endothelin receptor activity.
Results: Subconfluent human VSMCs were stimulated by ET-1 at different concentrations (1 nM-
1  μM). The activation of ERK1/2 was examined by immunofluorescence, Western blot and
phosphoELISA using specific antibody against phosphorylated ERK1/2 protein. ET-1 induced a
concentration- and time- dependent activation of ERK1/2 with a maximal effect at 10 min. It
declined to baseline level at 30 min. The ET-1-induced activation of ERK1/2 was completely
abolished by MEK1/2 inhibitors U0126 and SL327, and partially inhibited by the MEK1 inhibitor
PD98059. A dual endothelin receptor antagonist bosentan or the ETA antagonist BQ123 blocked
the ET-1 effect, while the ETB antagonist BQ788 had no significant effect. However, a selective ETB
receptor agonist, Sarafotoxin 6c (S6c) caused a time-dependent ERK1/2 activation with a maximal
effect by less than 20% of the ET-1-induced activation of ERK1/2. Increase in bosentan
concentration up to 10 μM further inhibited ET-1-induced activation of ERK1/2 and had a stronger
inhibitory effect than BQ123 or the combined use of BQ123 and BQ788. To further explore ET-1
intracellular signaling, PKC inhibitors (staurosporin and GF109203X), PKC-delta inhibitor
(rottlerin), PKA inhibitor (H-89), and phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin)
were applied. The inhibitors showed significant inhibitory effects on ET-1-induced activation of
ERK1/2. However, blockage of L-type Ca2+ channels or calcium/calmodulin-dependent protein
kinase II, chelating extracellular Ca2+ or emptying internal Ca2+ stores, did not affect ET-1-induced
activation of ERK1/2.
Conclusion: The ETA receptors predominate in the ET-1-induced activation of ERK1/2 in human
VSMCs, which associates with increments in intracellular PKC, PKA and PI3K activities, but not
Ca2+ signalling.
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Background
In the human cardiovascular system, endothelin-1 (ET-1)
is the most important isoform, which induces long-lasting
vasoconstriction and stimulates proliferation of vascular
smooth muscle cells (VSMCs) [1]. ET-1 acts on two G-pro-
tein coupled receptors: endothelin type A (ETA) and
endothelin type B (ETB), and plays an important role in
hypertension, vascular remodelling, cardiac hypertrophy
and coronary artery disease [2]. The ETA receptors locate
on VSMCs and mediate vasoconstriction, while the ETB
receptors primarily locate in vascular endothelial cells and
mediate transient vasodilation in vivo [3]. However, a sub-
population of contractile ETB receptors exist in the VSMCs
and mediate vasoconstriction [3,4]. The ETA receptor acti-
vates G proteins of Gq/11 and G12/13, which results in
the contractile and proliferation effects in VSMCs through
activation of diverse signaling molecules such as phos-
pholipase C (PLC), intracellular Ca2+, protein kinase C
(PKC), and extracellular signal-regulated kinase 1 and 2
(ERK1/2). Whereas, the ETB receptor stimulates the Gi and
the Gq/11 families in VSMCs and endothelial cells
[1,2,5,6]. ET-1 is non-selective agonist for both ETA and
ETB receptors, which may result in receptor signal cross-
talk in vascular physiology and pathology. However, there
is limited knowledge about this.
ERK1/2, also termed p44/42 MAPK (mitogen-activated
protein kinase), is one of the members of MAPK super-
family, which includes a family of serine/threonine kinase
associated with VSMCs contraction, proliferation, migra-
tion, differentiation, adhesion, collagen deposition and
survival [7]. Activation of either the ETA or the ETB receptor
results in phosphorylation of ERK1/2, which is an impor-
tant regulator for cellular proliferation, migration, differ-
entiation and vascular smooth muscle constriction [8-12].
A MAPK kinase (MEK) is required for the ERK1/2 phos-
phorylation of both threonine and tyrosine residues [13].
In the activated form, ERK1/2 transmits extracellular stim-
uli by phosphorylating a variety of substrates including
transcription factors and kinases. There is a paucity of
knowledge on intracellular signal mechanisms that ET-1
leads to activation of ERK1/2 in human VSMCs. Non-
receptor tyrosine kinase c-Src-independent small G pro-
tein Ras-Raf-dependent mechanisms have been reported
to mediate ET-1-induced ERK1/2 phosphorylation in cul-
tured mouse VSMCs [14]. Intracellular Ca2+ signals are
required for MAPK/ERK1/2 activation induced by angi-
otensin II in VSMCs [15-17]. However, ET-1-induced
vasoconstriction is not affected by calcium channel block-
ers [18]. Thus, Ca2+-independent contraction is suggested
to be associated with PKC, phosphoinositide 3-kinase
(PI3K), Rho kinase and MAPK [10,11,19]. The present
study was designed, by using a series of specific pharma-
cological inhibitors, to explore the intracellular signal
mechanisms that ET-1 leads to activation of ERK1/2 in
human VSMCs with special focus on the receptor signal-
ling. We have demonstrated that ETA receptors predomi-
nate over ETB  receptors in mediating ET-1-induced
activation of ERK1/2 in human VSMCs. This activation is
associated with PKC, PKA and PI3K activities, but not
intracellular Ca2+ signalling.
Results
Time course and concentration-dependent activation of 
ERK1/2 induced by ET-1
ET-1-induced activation of ERK1/2 was examined in
human aortic smooth muscle cells (HASMCs) at different
time points and ET-1 concentrations. There was a 2.6 fold
(p < 0.001) increase of phosphorylated ERK1/2 in cells
exposed to 1 μM of ET-1 for 5 min; the enhancement
reached a peak (3.6 fold, p < 0.001) at 10 min after expo-
sure to ET-1 (Figure 1A). Thereafter, the activities of ERK1/
2 induced by ET-1 rapidly declined, and returned to base-
line control value at 30 min after stimulation. As verified
by western blot (Figure 1B), there was an increase in
pERK1/2 after ET-1 treatment. The concentration effects of
ET-1 on ERK1/2 activation were investigated at 10 min. It
showed that ET-1 induced activation of ERK1/2 in a con-
centration-dependent manner from 1 nM to 1 μM (Figure
1C).
Roles of endothelin receptors in mediating ET-1-induced 
activation of ERK1/2
The roles of ETA and ETB receptors in mediating ET-1-
induced activation of ERK1/2 were studied by using
bosentan (a dual endothelin receptor antagonist), BQ123
(a selective peptide antagonist for the ETA receptor), and
BQ788 (a selective peptide antagonist for the ETB recep-
tor). To clarify if the ETB  receptors in HASMCs were
involved in ET-1- induced activation of ERK1/2, sarafo-
toxin 6c (S6c), a selective ETB  receptor agonist was
employed and the phosphorylation of ERK1/2 was exam-
ined by immunofluorescence and western blot (Figure 2B
and 2A). In figure 2B, there was a slight elevation of phos-
phorylated ERK1/2 (1.3 fold, p < 0.001) as observed at 5
min after exposure to 1 μM of S6c. This peaked at 10 min
(1.5 fold, p < 0.001), and quickly declined at 15 min (1.3
fold, p < 0.001). This slight transient increase of phospho-
rylated ERK1/2 was also produced by 100 nM of S6c and
verified by western blot for pERK1/2 (Figure 2A). BQ123
and bosentan significantly inhibited the increase in
pERK1/2 activities, while the ETB  receptor antagonist
BQ788 had no significant effect (Figure 2C and 2D). The
increase in phosphorylated ERK1/2 was significantly
inhibited by 5 μM of BQ123 (by 51.8%, Figure 2C), which
is consistent with the results of phosphoELISA assay (by
51.9%, Figure 2D) and western blot (by 56.2%) [see Addi-
tional file 1]. ET-1-induced ERK1/2 activation was also
significantly inhibited by combination of BQ123 and
BQ788 by 65.4% (Figure 2C in immunocytochemistry),
by 43.6% (Figure 2D in phophoELISA assay) and by
62.1% [see Additional file 1 in western blot]. ComparedBMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
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Time course and concentration-effects of ET-1 on activation of ERK1/2 Figure 1
Time course and concentration-effects of ET-1 on activation of ERK1/2. Cultured HASMCs were starved for 24 h in 
serum-free medium and then stimulated with ET-1. A, bar graph shows time-dependent activation of ERK1/2 by ET-1 at 1 μM. 
Phosphorylated ERK1/2 was determined by immunofluorescence with an anti-phospho-ERK1/2 antibody. B, representative 
autoradiograph of western blot showing the level of phosphorylated and total ERK1/2 from the samples treated with ET-1 at 0 
min, 5 min,10 min and 15 min. C, Bar graph shows concentration-dependent activation of ERK1/2 by ET-1 from 1 nM to 1 μM 
for 10 min. Phosphorylated ERK1/2 was determined by immunofluorescence with an anti-phospho-ERK1/2 antibody. The 
upper panels of A and C indicate representative images of immunofluorescence showing the phosphorylated ERK1/2 from the 
samples treated with ET-1 at different time points and various concentrations, respectively. The scale bar in each image repre-
sents 20 μm. Data represent mean ± S.E.M. *** p < 0.001 compared with the vehicle value. p = phosphorylated; t = total.
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to BQ123, a further inhibitory effect was seen in combina-
tion of BQ123 and BQ788 (p < 0.001, Figure 2C). Bosen-
tan at 5 μM and 10 μM significantly inhibited ET-1-
induced activation of ERK1/2 by 65.1% and 87.1%,
respectively (Figure 2D). At 10 μM bosentan had a
stronger inhibitory effect on ET-1-induced activation of
ERK1/2 than either BQ123 or combination of BQ123 and
BQ788 (p < 0.05, or p < 0.01, Figure 2D). This indicated
that ETB receptor antagonist BQ788 had no significant
inhibitory effect on ET-1-induced activation of ERK1/2 in
the absence of ETA  receptor antagonist BQ123, while
bosentan, a dual ET receptor agonist or combined use of
BQ123 and BQ788, further decreased ET-1-induced acti-
vation of ERK1/2.
Role of the MEK on ET-1-induced activation of ERK1/2
Three different MEK/ERK kinase inhibitors were used to
study ET-1-induced activation of ERK1/2 in HASMCs. As
shown in Figure 3A and 3B, U0126, a potent MEK1/2
inhibitor, at the concentration 1 and 10 μM completely
Roles of endothelin receptor subtypes in mediating ET-1-induced activation of ERK1/2 in HASMCs Figure 2
Roles of endothelin receptor subtypes in mediating ET-1-induced activation of ERK1/2 in HASMCs. Serum-
starved cells were stimulated with S6c for 5, 10 or 15 min or ET-1 for 10 min. 5 μM of BQ123, 5 μM of BQ788, 5 μM or 10 μM 
of bosentan were given for 30 min before addition of ET-1. A, representative autoradiograph of western blot showing the 
phosphorylated ERK1/2 and total ERK1/2 from samples treated with 100 nM of S6c at different time points. B, bar graph shows 
time-dependent activation of ERK1/2 by 1 μM of S6c. Phosphorylated ERK1/2 was determined by immunofluorescence with an 
anti-phospho-ERK1/2 antibody. C, bar graph shows inhibitory effects of ET receptor inhibitors on phosphorylated ERK1/2 
induced by 10 nM of ET-1. Phosphorylated ERK1/2 was determined by immunofluorescence with an anti-phospho-ERK1/2 anti-
body. D, inhibitory effects of ET receptor inhibitors on phosphorylated ERK1/2 activity induced by 10 nM of ET-1. Phosphor-
ylated ERK1/2 activity was determined by phosphoELISA assay as described in Methods. The upper panels of B and C indicate 
representative images of immunofluorescence showing the phosphorylated ERK1/2 from samples treated with S6c at different 
time points and treated with ET receptor inhibitors prior to addition of ET-1, respectively. The scale bar in each image repre-
sents 20 μm. Data represent mean ± S.E.M. *** p < 0.001 compared with the vehicle value (B). ** p < 0.01, *** p < 0.001 com-
pared with the ET-1-stimulated states after DMSO treatment (C,D). # p < 0.05, ## p < 0.01, ### p < 0.001; p = 
phosphorylated; t = total, ns = non-significant.
D
B
pERK1/2 
0min 5min 10min  15min 
A C
tERK1/2 
pERK1/2 
5min 10min 15min 
S6c 100nM 
0min 
0
50
100
150
200
250
300
***
***
ET-1
BQ123
BQ788
-
-
-
+
-
- -
-
+++
+
+
+
+
###
F
l
u
o
r
e
s
c
e
n
c
e
 
I
n
t
e
n
s
i
t
y
 
R
e
l
a
t
i
v
e
 
t
o
 
C
o
n
t
r
o
l
 
(
%
)
pERK1/2 
Control DMSO  BQ123  BQ788  BQ123+BQ788 
ET-1 
0min 5min 10min 15min
0
50
100
150
200 S6c 1μM
***
***
***
F
l
u
o
r
e
s
c
e
n
c
e
 
I
n
t
e
n
s
i
t
y
 
R
e
l
a
t
i
v
e
 
t
o
 
C
o
n
t
r
o
l
 
(
%
)
** ** **
***
0
50
100
150
200
250
DMSO BQ123 Bosentan
10uM
DMSO BQ123 BQ788 BQ123+788 5uM 10uM
R
e
l
a
t
i
v
e
 
p
E
R
K
1
/
2
 
a
c
t
i
v
i
t
y
 
(
%
 
C
o
n
t
r
o
l
)
Bosentan
ET-1
ns   ##
  #BMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
Page 5 of 13
(page number not for citation purposes)
inhibited ET-1-induced phosphorylation of ERK1/2 from
258% to 87% and 63%, respectively. SL327, another
selective inhibitor of MEK1 and MEK2 had similar degree
of inhibitory effects (Figure 3A). PD98059, a selective
inhibitor of MEK1, only partially inhibited ET-1-induced
phosphorylation of ERK1/2 from 258% to 153% at 1 μM,
and to 145% at 10 μM, respectively (Figure 3A). This sug-
gests that both MEK1 and MEK2 are required for ET-1 to
activate ERK1/2 in HASMCs. This is further supported by
phosphoELISA assay (Figure 3B) and western blot [see
Additional file 1]. Compared to PD98059, U0126 at 1 μM
had a significant stronger inhibitory effect (p < 0.001, Fig-
ure 3A). To clarify whether U0126 also inhibits phospho-
rylation of ERK1/2 in untreated control cells, the
phosphoELISA assay was used. It showed that in
untreated control HASMCs, U0126 at 1 μM did not signif-
Effects of MEK inhibitors on ET-1-induced activation of ERK1/2 in HASMCs Figure 3
Effects of MEK inhibitors on ET-1-induced activation of ERK1/2 in HASMCs. Serum-starved cells were treated with 
U0126, PD98059 or SL327 for 30 min prior to addition of ET-1. A, bar graph shows inhibitory effects of MEK inhibitors on 
phosphorylated ERK1/2 induced by 10 nM of ET-1. Phosphorylated ERK1/2 was determined by immunofluorescence with an 
anti-phospho-ERK1/2 antibody. B, inhibitory effects of MEK inhibitors on phosphorylated ERK1/2 activity induced by 10 nM of 
ET-1. Phosphorylated ERK1/2 activity was determined by phosphoELISA assay as described in Methods. The upper panel of A 
indicates representative images of immunofluorescence showing the phosphorylated ERK1/2 from the samples treated with 
MEK inhibitors prior to addition of ET-1. The scale bar in each image represents 20 μm. Data represent mean ± S.E.M. ** p < 
0.01, *** p < 0.001 compared with the ET-1-stimulated states after DMSO treatment. ### p < 0.001; p = phosphorylation, ns 
= non-significant.
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icantly modify ERK1/2 activity (Figure 3B). In ET-1-
treated HASMCs, U0126 significantly decreased the phos-
phorylated ERK1/2 level at the same concentration (Fig-
ure 3A and 3B).
Roles of PKC/PKA and small G proteins on ET-1-induced 
activation of ERK1/2
To further determine the upstream signaling involved in
the MEK/ERK pathway, we used pharmacological inhibi-
tors and examined the effects of PKC inhibitors (stau-
rosporin and GF109203X), PKC-delta inhibitor
(Rottlerin), PKA specific inhibitor (H-89), and PI3K
inhibitor (wortmannin) on ET-1-induced pERK1/2 activi-
ties (Figure 4). The activation of ERK1/2 was significantly
inhibited by 500 nM of staurosporin (93.2%), 10 μM of
GF 109203X (89.1%), 5 μM of Rottlerin (58.4%), 10 μM
of H-89 (83.8%), and 2 μM of Wortmannin (91.6%),
respectively (Figure 4A). Similar, results were obtained in
the phosphoELISA assay (Figure 4B).
Role of extracellular Ca2+ influx or intracellular Ca2+ 
release in mediating ET-1-induced activation of ERK1/2 in 
HASMCs
Ca2+, a second messenger, has a central role in activation
of various key cellular responses, including muscle con-
traction, cell proliferation, migration and adhesion [20].
To evaluate the role of intracellular Ca2+signaling in medi-
ating ET-1-induced activation of ERK1/2, nifedipine was
used to block external Ca2+ influx through L-type Ca2+
channels, 5 mM of EGTA was employed to chelate extra-
cellular Ca2+, and 1 μM of thapsigargin was used to cause
intracellular Ca2+ stores to become depleted. KN-62, a cal-
cium-calmodulin dependent protein kinase II (CAMKII)
inhibitor was also examined (Figure 5). The activation of
ERK1/2 was not affected by L-type Ca2+ channel blocker
(Figure 5A), chelating extracellular Ca2+ (Figure 5C), abol-
ishing intracellular Ca2+ release (Figure 5D), or inhibition
of CAMKII (Figure 5B). Replacing the medium with cal-
cium-free PBS [see Additional file 2] did not inhibit ET-1-
induced activation of ERK1/2. These indicated that extra-
cellular Ca2+ influx and Ca2+ released from internal stores
were not necessarily required for the ET-1-induced phos-
phorylation of ERK1/2 in HASMCs. This is further sup-
ported by the results from phosphoELISA assay (Figure
5E). To identify whether extracellular Ca2+ was chelated or
Ca2+ influx was decreased in our experiments, we used 1
μM of thapsigargin to induce extracellular Ca2+ influx
through store-operated Ca2+ channels (SOCC) [21]. We
found that thapsigargin resulted in an activation of ERK1/
2 in HASMCs as reported in RBL-1 cells [21]. The activa-
tion of ERK1/2 was abolished by 5 mM of EGTA [see Addi-
tional file 3]. This suggests that 5 mM of EGTA can
effectively chelate extracellular Ca2+and decrease Ca2+
influx in our experiments.
Discussion
The present study has revealed that ET-1 acts primarily via
the ETA receptors to induce phosphorylation of ERK1/2 in
HASMCs. The ET-1-induced response requires intracellu-
lar signal molecule PKC, PKA and PI3K activities, while it
is independent of intracellular calcium signaling.
ET-1-induced activation of ERK1/2 in HASMCs
ERK1/2 are important regulators of cell proliferation and
migration in VSMCs [8,9]. These basic cellular functions
are important for the formation of the neointima in path-
ologic states such as atherosclerosis. Many stimuli such as
mechanical stretch, growth factors, cytokines and activa-
tion of G protein-coupled receptors, can result in phos-
phorylation of ERK1/2 and its signal pathways. Recent
studies have demonstrated that ERK1/2 MAPK pathways
regulate Ca2+-dependent and Ca2+-independent contrac-
tion of VSMCs [10-12,19]. Intracellular ERK1/2 MAPK sig-
nal mechanisms play important roles in vascular
pathology and in the development of cardiovascular dis-
ease [22-24]. ET-1 not only remains the most potent and
long-lasting vasoconstrictor of human vessels, it also
induces proliferation of vascular smooth muscle cells
through activation of ERK1/2 [25] in pulmonary hyper-
tension, atherosclerosis, heart failure and restenosis
[2,26]. In human arterial smooth muscle cells, ET-1-
induced activation of ERK1/2 is much weaker in aortic
artery than in coronary artery [27]. This implies that small
arteries are more sensitive than large arteries. Unlike angi-
otensin II, which shows a rapid and transient increase in
activities of ERK1/2 [14], ET-1 induced a long-lasting
phosphorylation of ERK1/2 with a peaked at 10 min and
declined to baseline after 30 min in present study. The
activation of ERK1/2 by ET-1 might contribute to VSMC
proliferation in formation of new intima and thus it may
contribute to serve as an early "switch-on" mechanism for
cardiovascular disease development [28].
Roles of ET receptors in activation of ERK1/2 in HASMCs
The physiological and pathological effects of ET-1 are
mediated through two G protein-coupled receptors, ETA
and ETB. In human vasculature, ETA receptors predomi-
nate on the smooth muscle cells and mediate constriction,
whereas ETB receptors are expressed less than 15% on
these cells [29,30]. In-vivo studies suggest that both sub-
types of endothelin receptors can mediate vasoconstric-
tion in human resistance and capacitance vessels [31]. In
the present study, we found that ETA predominately medi-
ated ET-1-induced activation of ERK1/2. Although some
activation of ERK1/2 was obtained with the ETB-selective
agonist, S6c, the maximum response produced to S6c was
transient and less than 20% of the ET-1 effect. In addition,
BQ123, a selective antagonist of the ETA receptor [32], but
not ETB receptor antagonist BQ788, significantly inhibited
the activation of ERK1/2 induced by ET-1, suggesting thatBMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
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Effects of PKC, PKA and PI3 kinase inhibitors on ET-1-induced activation of ERK1/2 in HASMCs Figure 4
Effects of PKC, PKA and PI3 kinase inhibitors on ET-1-induced activation of ERK1/2 in HASMCs. Serum-starved 
cells were treated with 500 nM of staurosporin, 10 μM of GF109203X, 5 μM of rottlerin, 10 μM of H-89, or 2 μM of wortman-
nin for 30 min prior to addition of ET-1. A, bar graph shows inhibitory effects of inhibitors on phosphorylated ERK1/2 induced 
by 10 nM of ET-1. Phosphorylated ERK1/2 was determined by immunofluorescence with an anti-phospho-ERK1/2 antibody. B, 
inhibitory effects of inhibitors on phosphorylated ERK1/2 activity induced by 10 nM of ET-1. Phosphorylated ERK1/2 activity 
was determined by phosphoELISA assay as described in Methods. The upper panel of A indicates representative images of 
immunofluorescence showing the phosphorylated ERK1/2 from samples treated with inhibitors prior to addition of ET-1. The 
scale bar in each image represents 20 μm. Data represent mean ± S.E.M. * p < 0.05, **p < 0.01, *** p < 0.001 compared with 
the ET-1-stimulated states after DMSO treatment. p = phosphorylation.
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ET-1-induced activation of ERK1/2 is predominately
mediated by ETAreceptors. Compared to BQ123, a further
inhibition of ET-1-induced activation of ERK1/2 was
obtained in combination of BQ123 and BQ788. Bosen-
tan, a dual ETA and ETB receptor antagonist had a signifi-
cant stronger inhibitory effect on ET-1-induced activation
of ERK1/2 than either BQ123 or the combination of
BQ123 and BQ788. These results suggest that ET receptor
dimerization [33] might also occur in human VSMCs in
the presence of ET-1 as a bivalent ligand connecting two
receptors [34-36] and that the receptor cross-talk is
involved in the ET-1 effect. However, this requires more
studies to verify.
Upstream intracellular signal molecules involved in ET-1-
induced activation of ERK1/2
ERK1/2 activation requires a sequential activation of Ras,
Raf and MEK signal cascades [14,37]. MEK inhibitors
(U0126, PD98059 and SL327) were used to investigate
the role of upstream MEK in ET-1-induced activation of
Role of intracellular Ca2+ in mediating ET-1-induced activation of ERK1/2 in HASMCs Figure 5
Role of intracellular Ca2+ in mediating ET-1-induced activation of ERK1/2 in HASMCs. Serum-starved cells were 
treated with 10 nM of ET-1 for 10 min after different treatments. A, L-type Ca2+ channel inhibitor nifedipine was treated for 30 
min before addition of ET-1, bar graph shows effects of nifedipine at 2 μM and 10 μM on phosphorylated ERK1/2 induced by 
ET-1. Phosphorylated ERK1/2 was determined by immunofluorescence with an anti-phospho-ERK1/2 antibody. B, 10 μM of 
KN-62 was given for 30 min before addition of ET-1, bar graph shows effect of KN-62 on phosphorylated ERK1/2 induced by 
ET-1. C, 5 mM of the Ca2+ chelator EGTA was administered 15 min before addition of ET-1, bar graph shows effect of EGTA 
on phosphorylated ERK1/2 induced by ET-1. D, the cells were treated with 1 μM of thapsigargin with 5 mM of EGTA for 15 
min before addition of ET-1, bar graph shows effect of thapsigargin on phosphorylated ERK1/2 induced by ET-1 in the presence 
of EGTA. E, the treatment of cells with 10 μM of nifedipine, 5 mM of EGTA, or 1 μM of thapsigargin with 5 mM of EGTA 
before addition of ET-1, bar graph shows effects of the different treatments on phosphorylated ERK1/2 activity induced by ET-
1 as determined by the phosphoELISA assay. The upper panels of A, B, C and D indicate representative images of immunofluo-
rescence illustrating the phosphorylated ERK1/2 from samples given the different treatments prior to addition of ET-1. The 
scale bar in each image represents 20 μm. Data represent mean ± S.E.M. ns = non-significant. p = phosphorylation.
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ERK1/2. U0126, a highly selective inhibitor of MEK1/2
had the same potency as SL327 (another selective inhibi-
tor of MEK1/2), and completely inhibited ET-1-induced
activation of ERK1/2, whereas, PD98059, a selective
MEK1 inhibitor, only partially inhibited ET-1-induced
activation of ERK1/2. PKC, a family of serine/threonine
kinases, may be involved in the intracellular signal trans-
duction of MEK/ERK1/2 induced by ET-1. PKA is an
important second messenger. Cyclic AMP-independent
activation of PKA by ET-1 has been observed in rat aortic
smooth muscle cells [38]. On the other hand, G-protein-
coupled receptor signaling can be mediated through vari-
ous small G proteins. The Ras/Raf pathway is found to be
a proximal regulator of MEK [14,39]. PI3K, another
downstream effector of Ras [40], has been linked to a
diverse group of cellular functions, including cell growth,
proliferation, differentiation, motility, survival [41]. By
using selective inhibitors, the present study revealed that
PKC, PKA and PI3K were involved in activation of ERK1/
2 induced by ET-1 in HASMCs, which may provide targets
for drug discovery [42].
Intracellular Ca2+ signaling was not required for ET-1-
induced activation of ERK1/2
ET-1 stimulates phospholipase C-dependent hydrolysis of
PIP2 (phosphatidylinositol 4,5-bisphosphate) through G-
protein coupled receptors, leading to the generation of
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG), which are involved in intracellular Ca2+ mobiliza-
tion and PKC activation [5]. Recently, growing evidence
has shown that Ca2+ signaling is critical for activation of
ERK1/2 induced by angiotensin II in VSMCs [15-17].
However, the role of intracellular Ca2+ signaling in ET-1-
induced activation of ERK1/2 in human VSMCs remains
unclear. It has been reported that the activation of L-type
Ca2+  channels contributes to ET-1-induced sustained
phase of the Ca2+ response and the ability to generate
force [43]. Unlike angiotensin II, the present study
revealed that extracellular Ca2+ influx through L-type Ca2+
channels did not participate in ET-1-induced activation of
ERK1/2 in human VSMCs. To further investigate the
involvement of intracellular Ca2+  through other Ca2+
channels, which are suggested to be involved in ET-1-
mediated contractions of VSMC [43] and mitogenesis
[44], 5 mM of EGTA was used. Extracellular Ca2+ chelation
by EGTA did not affect activation of ERK1/2 induced by
ET-1. ET-1-induced Ca2+ release from intracellular stores is
triggered by the binding of IP3 to receptors on the sarco-
plasmic reticulum (SR). Depletion of intracellular Ca2+
stores can lead to a local Ca2+ flux through store-operated
Ca2+ channels (SOCC), which has been reported to initi-
ate the activation of ERK1/2 in RBL-1 cells [21]. Therefore,
in our studies, thapsigargin, an inhibitor to the SR Ca2+-
ATPase pump, which results in Ca2+ release and depletion
from internal stores, was applied together with 5 mM of
EGTA. The results showed that ERK1/2 activation by ET-1
did not require the participation of intracellular Ca2+
release. Studies have indicated that the CAMKII pathway
mediates G-protein coupled receptor ligand-depedent
activation of ERK1/2 in cultured VSM cells [36,45,46].
However, we observed that CAMKII pathway was proba-
bly not involved in the ET-1- induced activation of ERK1/
2 in human VSMCs as based on KN-62 inhibition experi-
ment. Using receptor-operated Ca2+ channel blockers LOE
908 and SK&F 96365, and L-type Ca2+ channels blocker
nifedipine, Kawanabe et al noted that ET-1-induced
ERK1/2 activiation involved a Ca2+ influx-dependent cas-
cade through Ca2+permeable nonselective cation chan-
nels (NSCCs) and SOCC, and a Ca2+influx-independent
cascade in rabbit carotid artery VSMCs [47]. The studies
showed that maximal effective concentration of nifed-
ipine has only 10% of the inhibition on ET-1-induced
increases in ERK1/2 activity. However, we did not find sig-
nificant changes of phosphorylated ERK1/2 induced by
ET-1 after treatment with nifedipine or chelation of extra-
cellular Ca2+.
Conclusion
In conclusion, we have demontrated that ET-1-induced
activation of ERK1/2 in human VSMCs is predominantly
mediated by ETA receptors through upstream signal mole-
cule PKC, PKA and PI3K, while it is independent of CAM-
KII and intracellular Ca2+  signaling. The endothelin
system plays key roles in hypertension, stoke and myocar-
dial infarction. Understanding the intracellular signaling
mechanisms of endothelin receptors may provide new
strategies for developing new drugs for cardiovascular dis-
eases.
Methods
Reagents and antibodies
ET-1 and S6c, a selective ETB receptor agonist [48], were
used at different concentration to stimulate phosphoryla-
tion (activation) of ERK1/2 in human VSMCs. To detect
the intracellular signal pathways involved in activation of
ERK1/2, a set of inhibitors were administered prior to
addition of stimulators. Bosentan, a dual endothelin
receptor antagonist was purchased from SynFine Research
(Ontario, Canada). ETA antagonist BQ123 and ETB antag-
onist BQ788 [4,48] were employed to examine the medi-
ation of endothelin receptors in activation of ERK1/2.
PD98059, a MEK1 inhibitor, and U0126, SL327, selective
inhibitors of both MEK1 and MEK2, were used as ERK
inhibitors. Staurosporin and GF109203X, PKC inhibitors;
Rottlerin, a PKC-delta inhibitor; H-89, a PKA inhibitor;
Wortmannin, a specific inhibitor of PI3K, were used as
protein kinase inhibitors or phosphoinositide 3-kinase
inhibitor. Nifedipine, a L-type Ca2+ channels inhibitor;
EGTA (ethylene glycol tetraacetic acid), a Ca2+ chelator;
thapsigargin, a sarco-endoplasmic reticulum Ca2+-ATPase
pump inhibitor; KN-62, a CAMKII inhibitor, were applied
to determine the involvement of Ca2+ signaling and CAM-BMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
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KII in activation of ERK1/2. The concentration of inhibi-
tors was determined by recommendation from product
data sheet and literatures. All drugs were purchased from
Sigma-Aldrich Co. (St. Louis, MO, USA). ET-1 and S6c
were dissolved in sterile water with 0.1% BSA; the other
reagents were dissolved in DMSO as a stock solution and
diluted in cell culture medium before use.
A monoclonal antibody for phospho-ERK1/2 (phospho
T183 + Y185) and a polyclonal antibody for total-ERK1/2
were obtained from Abcam plc. (Cambridge, UK). Poly-
clonal β-actin was purchased from Cell Signaling Technol-
ogy, Inc. (Boston, MA, USA).
Cell Culture and Experimental Protocol
HASMCs at the end of the tertiary culture stage were
obtained as a commercially available product from Cas-
cade Biologics Inc. (Portland, OR, USA). Cells were plated
in 75 cm2 tissue culture flasks at a density of 2.5 × 103 via-
ble cells/cm2 in Medium 231 supplemented with 5%
smooth muscle growth supplement (SMGS). Medium
231 and SMGS were purchased from Cascade Biologics
Inc. The cells were incubated in a 5% CO2 incubator at
37°C and the medium was replaced every other day until
the culture was approximately 80–90% confluent. Then
the cells were removed from the flasks with accutaseTM
Enzyme Cell Detachment Medium (eBioscience, Inc. San
Diego, CA, USA) and seeded onto 100-mm tissue culture
dish (Greiner Bio-One GmbH, Frickenhausen, Germany).
All experiments were performed with the cells of passages
6 to 9. HASMCs were allowed to grow to 70%–80% con-
fluence within 2 to 3 days, and maintained in medium
231 with 0.05% SMGS for 24 h, then we added vehicle or
ET-1, S6c at different concentration from 1 nM to 1 uM, or
with a time course at 5 min, 10 min, 15 min, 30 min, 1 h,
6 h and 24 h. Inhibitors or DMSO were treated for 30 min
prior to addition of ET-1.
Immunofluorescence Analysis to Detect phosphorylated 
ERK1/2
HASMCs were seeded at a density of 5 × 103/well in 4 well
NUNC Lab-Tek II Chamber Slides for 3 days and were
starved in medium 231 with 0.05% SMGS for 24 h. The
cells were stimulated with ET-1 or S6c at above indicated
time points after treatment with vehicle or inhibitors for
30 minutes, and then washed, fixed in 4% paraformalde-
hyde, permeabilized in PBS containing 4% Triton X-100.
The monoclonal primary antibody against phospho-
ERK1/2 (phospho T183 + Y185) was added to the cells at
1: 1000 dilution and incubated at room temperature for 1
h or overnight at 4°C, followed by adding fluorescein iso-
thiocynate (FITC)-conjugated goat anti-mouse secondary
antibody at 1:5000 dilution in dark according to the rec-
ommendation of the manufacturer. In the control experi-
ments, either the primary antibody or the secondary
antibody was omitted. After washing with PBS, ProLong
Gold antifade mounting reagent (Invitrogen Corporation,
Carlsbad, CA, USA) was added and the cells were sealed
with cover slip on the slide. The immunofluorescence
stained cells were observed under a laser scanning confo-
cal microscope (Nikon, C1plus, Nikon Instruments Inc.,
NY, USA) and analysed by ImageJ software http://
rsb.info.nih.gov/ij. The fluorescence intensity of cells was
measured at 4 preset areas of per sample and at least three
independent experiments were performed. The fluores-
cence intensity of each treated group was determined as
the percent increase over control, with the control nor-
malized to 100%. There was no change of fluorescence
intensity after cells were treated with inhibitors compared
with vehicle treatment [see Additional file 4].
Western Blot Analysis
About 70%–80% confluent HASMCs in 100-mm tissue
culture dishes were made quiescent by placing them in
medium 231 supplemented with 0.05% SMGS for 24 h
and harvested in cell extract denaturing buffer (BioSource,
USA) with addition of a phosphatase inhibitor cocktail
and protease inhibitor cocktail (Sigma, USA) after treat-
ment. Incubating cells at 4°C for 30 min, whole cell
lysates were sonicated for 2 min on ice, centrifuged at
15,000 × g at 4°C for 30 min, and the supernatants were
collected as protein samples. The protein concentrations
were determined using the protein assay reagents (Bio-
Rad, Hercules, CA, USA) and stored at -80°C until immu-
noblotting assay. The protein homogenates were diluted
1:1(v/v) with 2 × SDS sample buffer (Bio-Rad, USA). 25–
50 ug of total proteins were boiled for 10 min in SDS sam-
ple buffer and separated by 4–15% SDS Ready Gel Precast
Gels (Bio-Rad, USA) for 120 min at 100 v, and transferred
electrophoretically to nitrocellulose membranes (Bio-
Rad, USA) at 100 v for 60 min. The membrane was then
blocked for 1 h at room temperature with phosphate buff-
ered saline (PBS) containing 0.1% Tween-20 (Sigma,
USA) and 5% non-fat dried milk, and incubated with pri-
mary antibodies diluted 1:1000 overnight at 4°C, fol-
lowed by incubation with ECL anti-mouse or anti-rabbit
IgG, horseradish peroxidase-conjugated secondary anti-
bodies (Amersham Biosciences, Piscataway, NJ, USA)
diluted 1:10000 for 1 h at room temperature. The probed
proteins were developed by LumiSensor Chemilumines-
cent HRP Substrate ECL Western Blot Detection Reagent
(GenScript Corp., Piscataway, NJ, USA). To detect multi-
ple signals using a single membrane, the membrane was
incubated for 5–15 min at room temperature with restore
plus western blot stripping buffer (Pierce Biotechnology,
Inc., Rockford, IL. USA). The membranes were visualized
using a Fujifilm LAS-1000 Luminiscent Image Analyzer
(Stamford, CT, USA), and then quantification of band
intensity was analyzed with Image Gauge Ver. 4.0 (Fuji
Photo Film Co., LTD., Japan). Three independent experi-
ments were performed in duplicate.BMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
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Cell-based PhosphoELISA Analysis
HASMCs were seeded at a density of 3 × 103/well in 96-
well plate for 3 days and starved in medium 231 with
0.05% SMGS for 24 h. The cells were treated with vehicle
or different inhibitors for 30 min prior to the addition of
ET-1. After 10 min of ET-1 stimulation, the cells were fixed
and stored at 4°C until the performance of experiments.
Phosphorylated ERK1/2 was measured using a cell-based
ELISA Assay Kit (SABiosciences Corporation, MD, USA)
following the manufacturer's instructions. Phosphor-
ylated ERK1/2 activity was presented as a relative extent to
the level of total ERK1/2. Independent experiments were
done in duplicate or triplicate and were repeated at least
three times.
Statistical Analysis
Comparison between two groups was performed using
two-tailed unpaired Student's t-test with Welch's correc-
tion. For more than two groups one-way ANOVA fol-
lowed by Dunnett's post test was used. A p-value, less than
0.05 was considered to be significant. Results were pre-
sented as mean ± SEM. At least 3 different samples or
independent experiments were analyzed in each group.
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Additional file 1
Inhibitory effects of BQ123 and U0126 on pERK1/2 activity in HAS-
MCs. The data provided represent the Western Blot analysis of inhibitory 
effects of ETA receptor inhibitor BQ123 and MEK inhibitor U0126 on ET-
1-induced phosphorylation of ERK1/2. 24 h Serum-starved cells were 
stimulated with 10 nM of ET-1 for 10 min after cells were treated with 
inhibitors for 30 min. Phosphorylated ERK1/2 activity was determined by 
western blot with an anti-phospho-ERK1/2 antibody, and presented as a 
relative extent to the level of β-actin. A, bar graph shows inhibitory effects 
of 5 μM of ETA/ETB receptor inhibitors on phosphorylated ERK1/2 activity 
induced by ET-1. B, bar graph shows inhibitory effect of 1 μM of U0126 
on phosphorylated ERK1/2 activity induced by ET-1. The upper panels of 
A and B indicate representative autoradiographs of western blot showing 
phosphorylated ERK1/2 and β-actin. Data represent mean ± S.E.M. * p 
< 0.05, ** p < 0.01 compared with the ET-1-stimulated states after 
DMSO treatment. p = phosphorylation, ns = non-significant.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2121-10-52-S1.pdf]
Additional file 2
Effect of ET-1 on activation of ERK1/2 in HASMCs in the absence of 
external Ca2+. The data provided represent the immunofluorescence anal-
ysis of ET-1-induced phosphorylation of ERK1/2 in the absence of external 
Ca2+by replacing culture medium with PBS. Serum-starved cells were 
placed in the presence or absence of external Ca2+ for 3 min by replacing 
culture medium with PBS plus 1 mM EGTA prior to addition of ET-1. 
Phosphorylated ERK1/2 was determined at 10 min after the addition of 
10 nM of ET-1 by immunofluorescence with an anti-phospho-ERK1/2 
antibody. The bar graph shows effect of ET-1 on phosphorylated ERK1/2 
in the absence of extracellular Ca2+. The fluorescence intensities of phos-
phorylated ERK1/2 are expressed relative to the quiescent state in the pres-
ence of external Ca2+. The upper panel indicates representative images of 
immunofluorescence showing the phosphorylated ERK1/2 from samples 
given the different treatments. Data represent the mean ± S.E.M. *** p 
< 0.001. ns = non-significant.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2121-10-52-S2.pdf]
Additional file 3
The Ca2+ chelator EGTA abolished thapsigargin-induced activation of 
ERK1/2 in ET-1 untreated starved cells. The data provided represent the 
immunofluorescence analysis of inhibitory effect of the Ca2+ chelator 
EGTA on extracellular Ca2+influx through thapsigargin-induced store-
operated Ca2+ channels. Serum-starved cells were treated with 1 μM of 
thapsigargin with or without 5 μM of EGTA for 15 min. Phosphorylated 
ERK1/2 was determined by immunofluorescence with an anti-phospho-
ERK1/2 antibody. The bar graph shows effect of thapsigargin on phospho-
rylated ERK1/2 in the presence or in the absence of EGTA. The upper 
panel indicates representative images of immunofluorescence showing the 
phosphorylated ERK1/2 from samples given the different treatments. Data 
represent mean ± S.E.M. *** p < 0.001 compared with the vehicle value.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2121-10-52-S3.pdf]
Additional file 4
Effects of the inhibitors used in the present study on the activities of 
ERK1/2 in ET-1 untreated cells. The data provided represent the 
immunofluorescence analysis of the stability of fluorescence intensity after 
cells were treated with inhibitors compared with vehicle treatment. 
Serum-starved cells were treated with variety of inhibitors indicated or 
DMSO for 30 min. Phosphorylated ERK1/2 was determined by immun-
ofluorescence with an anti-phospho-ERK1/2 antibody. The bar graph 
shows no significant effects of the inhibitors on phosphorylated ERK1/2 in 
ET-1 untreated control cells. The upper panel indicates representative 
images of immunofluorescence showing the phosphorylated ERK1/2 from 
samples treated with different inhibitors. Data represent mean ± S.E.M.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2121-10-52-S4.pdf]BMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
Page 12 of 13
(page number not for citation purposes)
References
1. Marasciulo FL, Montagnani M, Potenza MA: Endothelin-1: the yin
and yang on vascular function.  Curr Med Chem 2006,
13(14):1655-1665.
2. Schneider MP, Boesen EI, Pollock DM: Contrasting actions of
endothelin ET(A) and ET(B) receptors in cardiovascular dis-
ease.  Annu Rev Pharmacol Toxicol 2007, 47:731-759.
3. Masaki T: Historical review: Endothelin.  Trends Pharmacol Sci
2004, 25(4):219-224.
4. Adner M, Uddman E, Cardell LO, Edvinsson L: Regional variation
in appearance of vascular contractile endothelin-B receptors
following organ culture.  Cardiovasc Res 1998, 37:254-262.
5. Cramer H, Schmenger K, Heinrich K, Horstmeyer A, Böning H, Breit
A, Piiper A, Lundstrom K, Müller-Esterl W, Schroeder C: Coupling
of endothelin receptors to the ERK/MAP kinase pathway.
Roles of palmitoylation and G(alpha)q.  Eur J Biochem 2001,
268(20):5449-5459.
6. Gohla A, Schultz G, Offermanns S: Role for G(12)/G(13) in ago-
nist-induced vascular smooth muscle cell contraction.  Circ
Res 2000, 87(3):221-227.
7. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Ber-
man K, Cobb MH: Mitogen-activated protein (MAP) kinase
pathways: regulation and physiological functions.  Endocr Rev
2001, 22(2):153-183.
8. Liu B, Ryer EJ, Kundi R, Kamiya K, Itoh H, Faries PL, Sakakibara K,
Kent KC: Protein kinase C-delta regulates migration and pro-
liferation of vascular smooth muscle cells through the extra-
cellular signal-regulated kinase 1/2.  J Vasc Surg 2007,
45(1):160-168.
9. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H: Role
of JNK, p38, and ERK in platelet-derived growth factor-
induced vascular proliferation, migration, and gene expres-
sion.  Arterioscler Thromb Vasc Biol 2003, 23(5):795-801.
10. D'Angelo G, Adam LP: Inhibition of ERK attenuates force devel-
opment by lowering myosin light chain phosphorylation.  Am
J Physiol Heart Circ Physiol 2002, 282(2):H602-H610.
11. Dessy C, Kim I, Sougnez CL, Laporte R, Morgan KG: A role for
MAP kinase in differentiated smooth muscle contraction
evoked by alpha-adrenoceptor stimulation.  Am J Physiol 1998,
275(4 Pt 1):C1081-C1086.
12. Luo G, Jamali R, Cao YX, Edvinsson L, Xu CB: Vascular endothelin
ET(B) receptor-mediated contraction requires phosphoryla-
tion of ERK1/2 proteins.  Eur J Pharmacol 2006, 538(1–3):124-131.
13. Whitmarsh AJ, Davis RJ: Transcription factor AP-1 regulation
by mitogen-activated protein kinase signal transduction
pathways.  J Mol Med 1996, 74(10):589-607.
14. Yogi A, Callera GE, Montezano AC, Aranha AB, Tostes RC, Schiffrin
EL, Touyz RM: Endothelin-1, but not Ang II, activates MAP
kinases through c-Src independent Ras-Raf dependent path-
ways in vascular smooth muscle cells.  Arterioscler Thromb Vasc
Biol 2007, 27(9):1960-1967.
15. Lucchesi PA, Bell JM, Willis LS, Byron KL, Corson MA, Berk BC:
Ca(2+)-dependent mitogen-activated protein kinase activa-
tion in spontaneously hypertensive rat vascular smooth mus-
cle defines a hypertensive signal transduction phenotype.
Circ Res 1996, 78(6):962-970.
16. Eguchi S, Matsumoto T, Motley ED, Utsunomiya H, Inagami T: Iden-
tification of an essential signaling cascade for mitogen-acti-
vated protein kinase activation by angiotensin II in cultured
rat vascular smooth muscle cells. Possible requirement of
Gq-mediated p21ras activation coupled to a Ca2+/calmodu-
lin-sensitive tyrosine kinase.  J Biol Chem 1996,
271(24):14169-14175.
17. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsu-
nomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo
F, Inagami T: Calcium-dependent epidermal growth factor
receptor transactivation mediates the angiotensin II-
induced mitogen-activated protein kinase activation in vas-
cular smooth muscle cells.  J Biol Chem 1998, 273(15):8890-8896.
18. McNair LL, Salamanca DA, Khalil RA: Endothelin-1 promotes
Ca2+  antagonist-insensitive coronary smooth muscle con-
traction via activation of epsilon-protein kinase C.  Hyperten-
sion 2004, 43(4):897-904.
19. Lee HM, Won KJ, Kim J, Park HJ, Kim HJ, Roh HY, Lee SH, Lee CK,
Kim B: Endothelin-1 induces contraction via a Syk-mediated
p38 mitogen-activated protein kinase pathway in rat aortic
smooth muscle.  J Pharmacol Sci 2007, 103(4):427-433.
20. Berridge MJ, Bootman MD, Roderick HL: Calcium signalling:
dynamics, homeostasis and remodelling.  Nat Rev Mol Cell Biol
2003, 4(7):517-529.
21. Chang WC, Di Capite J, Singaravelu K, Nelson C, Halse V, Parekh AB:
Local Ca2+  influx through Ca2+  release-activated (CRAC)
channels stimulates production of an intracellular messen-
ger and an intercellular pro-inflammatory signal.  J Biol Chem
2008, 283(8):4622-4631.
22. Kim S, Iwao H: Molecular and cellular mechanisms of angi-
otensin II-mediated cardiovascular and renal diseases.  Phar-
macol Rev 2000, 52(1):11-34.
23. Lee KH, Lim S, Kang SM, Kim DH, Cho HK, Chung JH, Kwon HM,
Chung H, Lee H, Jang Y, Hwang KC: Antiproliferative mecha-
nisms of raxofelast (IRFI-016) in H2O2-stimulated rat aortic
smooth muscle cells.  Eur J Pharmacol 2004, 484(2–3):119-125.
24. Cui MZ, Zhao G, Winokur AL, Laag E, Bydash JR, Penn MS, Chisolm
GM, Xu X: Lysophosphatidic acid induction of tissue factor
expression in aortic smooth muscle cells.  Arterioscler Thromb
Vasc Bio 2003, 23(2):224-230.
25. Zeidan A, Broman J, Hellstrand P, Swärd K: Cholesterol depend-
ence of vascular ERK1/2 activation and growth in response to
stretch: role of endothelin-1.  Arterioscler Thromb Vasc Biol 2003,
23(9):1528-1534.
26. Lüscher TF, Barton M: Endothelins and endothelin receptor
antagonists: therapeutic considerations for a novel class of
cardiovascular drugs.  Circulation 2000, 102(19):2434-2340.
27. Yoshizumi M, Kim S, Kagami S, Hamaguchi A, Tsuchiya K, Houchi H,
I w a o  H , K i d o H ,  T a ma k i  T :  Effect of endothelin-1 (1–31) on
extracellular signal-regulated kinase and proliferation of
human coronary artery smooth muscle cells.  Br J Pharmacol
1998, 125(5):1019-1027.
28. Hazzalin CA, Mahadevan LC: MAPK-regulated transcription: a
continuously variable gene switch?  Nat Rev Mol Cell Biol 2002,
3(1):30-40.
29. Davenport AP, O'Reilly G, Kuc RE: Endothelin ETA and ETB
mRNA and receptors are expressed by smooth muscle in
the human vasculature: majority of the ETA subtype.  Br J Phar-
macol 1995, 114(6):1110-1116.
30. Maguire JJ, Davenport AP: ETA receptor-mediated constrictor
responses to endothelin peptides in human blood vessels in
vitro.  Br J Pharmacol 1995, 115(1):191-197.
31. Haynes WG, Strachan FE, Webb DJ: Endothelin ETA and ETB
receptors cause vasoconstriction of human resistance and
capacitance vessels in vivo.  Circulation 1995, 92(3):357-363.
32. Davenport AP: Update on endothelin receptor nomenclature.
Pharmacol Rev 2002, 54(2):219-226.
33. Gregan B, Jürgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann
M, Rosenthal W, Oksche A: Ligand-dependent differences in the
internalization of endothelin A and endothelin B receptor
heterodimers.  J Biol Chem 2004, 279(26):27679-27687.
34. Sakamoto A, Yanagisawa M, Sawamura T, Enoki T, Ohtani T, Sakurai
T, Nakao K, Toyo-oka T, Masaki T: Distinct subdomains of
human endothelin receptors determine their selectivity to
endothelinA-selective antagonist and endothelinB-selective
agonists.  J Biol Chem 1993, 268(12):8547-8553.
35. Harada N, Himeno A, Shigematsu K, Sumikawa K, Niwa M: Endothe-
lin-1 binding to endothelin receptors in the rat anterior pitu-
itary gland: possible formation of an ETA-ETB receptor
heterodimer.  Cell Mol Neurobiol 2002, 22(2):207-226.
36. Pérez-Rivera AA, Fink GD, Galligan JJ: Vascular reactivity of
mesenteric arteries and veins to endothelin-1 in a murine
model of high blood pressure.  Vascul Pharmacol 2005,
43(1):1-10.
37. Ginnan R, Singer HA: CaM kinase II-dependent activation of
tyrosine kinases and ERK1/2 in vascular smooth muscle.  Am
J Physiol Cell Physiol 2002, 282(4):C754-761.
38. Dulin NO, Niu J, Browning DD, Ye RD, Voyno-Yasenetskaya T:
Cyclic AMP-independent activation of protein kinase A by
vasoactive peptides.  J Biol Chem 2001, 276(24):20827-20830.
39. Kolch W: Coordinating ERK/MAPK signalling through scaf-
folds and inhibitors.  Nat Rev Mol Cell Biol 2005, 6(11):827-837.
40. Marshall CJ: Ras effectors.  Curr Opin Cell Biol 1996, 8(2):197-204.
41. Vanhaesebroeck B, Leevers S, Ahmadi K, Timms J, Katso R, Driscoll
P, Woscholski R, Parker P, Waterfield M: Synthesis and functionPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cell Biology 2009, 10:52 http://www.biomedcentral.com/1471-2121/10/52
Page 13 of 13
(page number not for citation purposes)
of 3-phosphorylated inositol lipids.  Annu Rev Biochem 2001,
70:535-602.
42. Force T, Kuida K, Namchuk M, Parang K, Kyriakis JM: Inhibitors of
protein kinase signaling pathways: emerging therapies for
cardiovascular disease.  Circulation 2004, 109(10):1196-1205.
43. Pollock DM, Keith TL, Highsmith RF: Endothelin receptors and
calcium signaling.  FASEB J 1995, 9(12):1196-1204.
44. Kawanabe Y, Hashimoto N, Masaki T: Ca(2+) channels involved in
endothelin-induced mitogenic response in carotid artery
vascular smooth muscle cells.  Am J Physiol Cell Physiol 2002,
282(2):C330-337.
45. Abraham ST, Benscoter HA, Schworer CM, Singer HA: A role for/
calmodulin-dependent protein kinase II in the mitogen-acti-
vated protein kinase signaling cascade of cultured rat aortic
vascular smooth muscle cells.  Circ Res 1997, 81(4):575-584.
46. Ginnan R, Pfleiderer PJ, Pumiglia K, Singer HA: PKC-delta and
CaMKII-delta 2 mediate ATP-dependent activation of ERK1/
2 in vascular smooth muscle.  Am J Physiol Cell Physiol 2004,
286(6):C1281-1289.
47. Kawanabe Y, Hashimoto N, Masaki T: Extracellular Ca2+ influx
and endothelin-1-induced intracellular mitogenic cascades in
rabbit internal carotid artery vascular smooth muscle cells.
J Cardiovasc Pharmacol 2002, 40(2):307-314.
48. Adner M, Cantera L, Ehlert F, Nilsson L, Edvinsson L: Plasticity of
contractile endothelin-B receptors in human arteries after
organ culture.  Br J Pharmacol 1996, 119(6):1159-1166.